RANK and RANK ligand expression in primary human osteosarcoma

Area of Science:

• Oncology
• Bone Biology
• Immunology

Background:

• Receptor activator of nuclear factor kappa-B ligand (RANKL) drives osteoclast formation and is targeted in bone metastases.
• Giant cell tumor of bone (GCTB) shows high RANKL/RANK expression, with denosumab demonstrating efficacy.
• The role of the RANKL pathway in primary bone tumors like osteosarcoma (OS) requires investigation.

Purpose of the Study:

• To assess human RANKL and RANK expression in primary osteosarcoma (OS) tumors.
• To compare RANKL/RANK expression in OS with that in GCTB.
• To evaluate the potential therapeutic implications of targeting the RANKL pathway in OS.

Main Methods:

• Immunohistochemistry (IHC) and flow cytometry were used to detect RANKL and RANK.
• Specific monoclonal antibodies (mAbs) were employed for validated detection.
• Expression levels and staining intensity were quantified in human OS samples.

Main Results:

• RANKL expression was detected in 68% of OS tumors via IHC, but with low intensity and in <10% of tumor cells in 37% of cases.
• RANK expression was absent in OS tumor cells but present in osteoclasts and myeloid precursors within OS samples.
• RANKL and RANK expression in OS was significantly lower than in GCTB.

Conclusions:

• Osteosarcoma cells express RANKL, potentially contributing to osteoclast-mediated bone pathology.
• The absence of RANK in OS cells suggests autocrine signaling is not active, and anti-RANKL therapy may not directly target OS tumor cells.
• Further research is warranted to explore the indirect effects of anti-RANKL therapy on bone complications in OS.